Antibody Drug Conjugate Analytics Patents: Who Leads and Where Filing Concentrates
24.1% of the field sits with five companies — 4,069 of 16,867 records concentrate at the top, while a long tail of single-and-few-filing entrants fills the rest of the ranked 100. Publications ran from 769 in 2017 to a peak of 1,063 in 2020, then eased to 628 by 2024 (-31% from 915 in 2021). 2025 and 2026 figures are still incomplete under the roughly 18-month publication lag and should not be read as a continued decline.
- 1REGENERON PHARMACEUTICALS INC5.4%
- 2JANSSEN BIOTECH INC5.2%
- 3AMGEN INC4.7%
- 4GENENTECH INC4.6%
- 5HALOZYME INC4.2%
See the full antibody drug conjugate analytics analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in antibody drug conjugate analytics?
One assignee leads with 913 records in this dataset, ahead of fifth place at 711 and tenth place at 360. The top five combined account for 24.1% of all 16,867 records in scope, and the top ten reach 38.1%. That leaves the majority of records spread across a long tail of the ranked 100 assignees, so leadership at the very top does not mean the field is closed to new entrants.
Is filing activity in ADC analytics still growing?
Filing peaked in 2020 at 1,063 records and has since eased, falling from 915 in 2021 to 628 in 2024, a 31% decline over that span. 2025 and 2026 figures are still incomplete because publication typically lags actual filing by around 18 months, so the most recent years understate real activity. Treat 2024 as the last year with a reasonably complete picture rather than reading the tail as a hard trend.
What technology areas dominate ADC analytics patents?
Most records carry IPC classes tied to the underlying biologic rather than the analytical method itself: C07K (peptides & proteins) covers 64.3% of the 16,867 records and A61K (medicinal preparations) covers 59.6%. Analytical-testing classes are comparatively thin — G01N covers 17.3% and C12Q just 5.2% — which points to method-level claims, such as specific monitoring or reference-standard techniques, as a relatively under-built layer.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Antibody Drug Conjugate Analytics covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.